Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002908 · ClinicalTrials.gov registry record · Phase 2
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002908: Completed Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00002908 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002908, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of bryostatin 1 in treating patients who have relapsed non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Interventions
- DRUG bryostatin 1
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-12 |
| Est. Completion | 2001-11 |
| Phase | Phase 2 |
What the finished NCT00002908 record still lists
NCT00002908 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which bryostatin 1 is the first listed.
NCT00002908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002908 about?
NCT00002908 is a clinical study titled "Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of bryostatin 1 in treating patients who have relapsed non-Hodgkin's l...
What is the current status of trial NCT00002908?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-12. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00002908?
The interventions under investigation include: bryostatin 1 (DRUG), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00002908?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia